SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
January 18, 2018
|Xtant Medical Holdings, Inc.|
|(Exact Name of Registrant as Specified in Its Charter) |
|(State or Other Jurisdiction of Incorporation) |
|(Commission File Number)
||(IRS Employer Identification No.)|
|664 Cruiser Lane
|(Address of Principal Executive Offices)
|(Registrant’s Telephone Number, Including Area Code)|
|(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ¨
|Item 7.01||Regulation FD Disclosure.
The Company has issued a press release
on January 18, 2018, entitled “Xtant Medical Enters into Restructuring and Exchange Agreement with All Holders of Outstanding
Convertible Notes,” which is attached as Exhibit 99.1 and incorporated herein.
The information in this Item 7.01 and the
document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of
the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities
of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall
be expressly set forth by specific reference in such a filing.
|Item 9.01.||Financial Statements and Exhibits.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|Dated: January 18, 2018
||XTANT MEDICAL HOLDINGS, INC.|
||By: /s/ Carl D. O’Connell|
||Name: Carl D. O’Connell|
||Title: Chief Executive Officer |